S&P 500   3,872.78 (+0.72%)
DOW   31,229.33 (+0.62%)
QQQ   289.61 (+0.28%)
T   21.18 (+0.43%)
F   11.27 (+1.90%)
DIS   96.74 (+0.69%)
AMC   12.63 (+0.48%)
PFE   52.83 (+0.15%)
PYPL   73.43 (+0.26%)
NFLX   183.60 (-0.25%)
S&P 500   3,872.78 (+0.72%)
DOW   31,229.33 (+0.62%)
QQQ   289.61 (+0.28%)
T   21.18 (+0.43%)
F   11.27 (+1.90%)
DIS   96.74 (+0.69%)
AMC   12.63 (+0.48%)
PFE   52.83 (+0.15%)
PYPL   73.43 (+0.26%)
NFLX   183.60 (-0.25%)
S&P 500   3,872.78 (+0.72%)
DOW   31,229.33 (+0.62%)
QQQ   289.61 (+0.28%)
T   21.18 (+0.43%)
F   11.27 (+1.90%)
DIS   96.74 (+0.69%)
AMC   12.63 (+0.48%)
PFE   52.83 (+0.15%)
PYPL   73.43 (+0.26%)
NFLX   183.60 (-0.25%)
S&P 500   3,872.78 (+0.72%)
DOW   31,229.33 (+0.62%)
QQQ   289.61 (+0.28%)
T   21.18 (+0.43%)
F   11.27 (+1.90%)
DIS   96.74 (+0.69%)
AMC   12.63 (+0.48%)
PFE   52.83 (+0.15%)
PYPL   73.43 (+0.26%)
NFLX   183.60 (-0.25%)

SI-BONE Stock Forecast, Price & News

-0.03 (-0.22%)
(As of 07/6/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
85,517 shs
Average Volume
167,170 shs
Market Capitalization
$458.06 million
P/E Ratio
Dividend Yield
Price Target

SI-BONE MarketRank™ Forecast

Analyst Rating
3.00 Rating Score
133.5% Upside
$31.57 Price Target
Short Interest
6.41% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Selling Shares
$369,455 Sold Last Quarter
Proj. Earnings Growth
From ($1.93) to ($1.72) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.21 out of 5 stars

Medical Sector

269th out of 1,433 stocks

Surgical & Medical Instruments Industry

35th out of 137 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive SIBN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SI-BONE and its competitors with MarketBeat's FREE daily newsletter.

SI-BONE logo


SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

SIBN Stock News Headlines

Aurora Spine Has Three Shots On Goal
SI-BONE: Q4 Earnings Insights
SI-BONE guides Q4 and FY21 revenue above consensus
Is SI-BONE, Inc. (SIBN) Going to Burn These Hedge Funds?
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$90.15 million
Book Value
$4.01 per share


Free Float
Market Cap
$458.06 million
Not Optionable

SI-BONE Frequently Asked Questions

Should I buy or sell SI-BONE stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SI-BONE stock.
View analyst ratings for SI-BONE
or view top-rated stocks.

What is SI-BONE's stock price forecast for 2022?

6 brokerages have issued 1 year price objectives for SI-BONE's shares. Their SIBN stock forecasts range from $25.00 to $36.00. On average, they predict SI-BONE's share price to reach $31.57 in the next twelve months. This suggests a possible upside of 133.5% from the stock's current price.
View analysts' price targets for SI-BONE
or view top-rated stocks among Wall Street analysts.

How has SI-BONE's stock performed in 2022?

SI-BONE's stock was trading at $22.21 at the beginning of 2022. Since then, SIBN stock has decreased by 39.1% and is now trading at $13.52.
View the best growth stocks for 2022 here

When is SI-BONE's next earnings date?

SI-BONE is scheduled to release its next quarterly earnings announcement on Monday, August 1st 2022.
View our earnings forecast for SI-BONE

How were SI-BONE's earnings last quarter?

SI-BONE, Inc. (NASDAQ:SIBN) announced its earnings results on Monday, May, 9th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.09. The business had revenue of $22.44 million for the quarter, compared to analysts' expectations of $22.37 million. SI-BONE had a negative trailing twelve-month return on equity of 44.52% and a negative net margin of 67.00%. During the same period last year, the firm posted ($0.37) earnings per share.
View SI-BONE's earnings history

What guidance has SI-BONE issued on next quarter's earnings?

SI-BONE updated its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $106.00 million-$108.00 million, compared to the consensus revenue estimate of $107.35 million.

Who are SI-BONE's key executives?

SI-BONE's management team includes the following people:
  • Ms. Laura A. Francis MBA, CEO & Director (Age 55, Pay $879.74k) (LinkedIn Profile)
  • Mr. Anshul Maheshwari, Chief Financial Officer (Age 44, Pay $511.05k)
  • Mr. Anthony J. Recupero, Pres of Commercial Operations (Age 63, Pay $665.91k) (LinkedIn Profile)
  • Mr. Michael A. Pisetsky, Sr. VP of Operations & Admin., Sec. and Chief Legal Officer (Age 44) (LinkedIn Profile)
  • Dr. Scott A. Yerby, Sr. VP of Engineering & CTO (Age 54)
  • Mr. Joseph W. Powers, VP of Corp. Marketing (Age 62)
  • Dr. Daniel Joseph Cher, Sr. VP of Clinical & Regulatory Affairs (Age 57)
  • Dr. W. Carlton Reckling, Chief Medical Officer & VP of Medical Affairs (Age 60)
  • Mr. Nikolas F. Kerr, Sr. VP of Product, Strategy & Bus. Devel. (Age 50)
  • Ms. Joyce Goto, VP & Corp. Controller (Age 48)

What is Jeffrey Dunn's approval rating as SI-BONE's CEO?

10 employees have rated SI-BONE CEO Jeffrey Dunn on Glassdoor.com. Jeffrey Dunn has an approval rating of 41% among SI-BONE's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of SI-BONE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SI-BONE investors own include (HON), CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Raytheon Technologies (RTX), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Alibaba Group (BABA), Cisco Systems (CSCO) and CSX (CSX).

When did SI-BONE IPO?

(SIBN) raised $84 million in an initial public offering on Wednesday, October 17th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is SI-BONE's stock symbol?

SI-BONE trades on the NASDAQ under the ticker symbol "SIBN."

How do I buy shares of SI-BONE?

Shares of SIBN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SI-BONE's stock price today?

One share of SIBN stock can currently be purchased for approximately $13.52.

How much money does SI-BONE make?

SI-BONE (NASDAQ:SIBN) has a market capitalization of $458.06 million and generates $90.15 million in revenue each year. The company earns $-56,570,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis.

How many employees does SI-BONE have?

SI-BONE employs 352 workers across the globe.

How can I contact SI-BONE?

SI-BONE's mailing address is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. The official website for SI-BONE is www.si-bone.com. The company can be reached via phone at (408) 207-0700 or via email at investors@si-bone.com.

This page (NASDAQ:SIBN) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.